Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ZAHEER ASLAM

Allopathic & Osteopathic Physicians Psychiatry & Neurology Addiction Psychiatry

NPI
1609950468
CMS profile
466115
Location
FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,086.46

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $778.57 4
Food and Beverage $307.89 6

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $1,035.80 8
Janssen Pharmaceuticals, Inc $50.66 2

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ZAHEER ASLAM

NPI 1609950468 · CMS profile ID 466115

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Addiction Psychiatry

FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609950468?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ZAHEER ASLAM, NPI 1609950468, CMS profile ID 466115. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609950468?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ZAHEER ASLAM, NPI 1609950468, CMS profile ID 466115. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609950468?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ZAHEER ASLAM, NPI 1609950468, CMS profile ID 466115, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1609950468?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $1,086.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $20.2004/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987873845 CMS
Merck Sharp & Dohme LLC $34.9801/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048407845 CMS
Merck Sharp & Dohme LLC $49.3901/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048407983 CMS
Merck Sharp & Dohme LLC $75.2801/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048407985 CMS
Merck Sharp & Dohme LLC $49.3901/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048407995 CMS
Merck Sharp & Dohme LLC $123.4701/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048407981 CMS
Merck Sharp & Dohme LLC $167.3901/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048407987 CMS
Merck Sharp & Dohme LLC $301.0001/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048761615 CMS
Merck Sharp & Dohme LLC $234.9001/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048761619 CMS
Janssen Pharmaceuticals, Inc $30.4601/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987873853 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $37.13 2
PY2020 $65.52 3
PY2021 $42.09 2
PY2023 $1,086.46 10
PY2024 $84.98 5
PY2025 $36.17 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $312,010.46 23
PY2024 Principal investigator $269,570.91 25
PY2023 Principal investigator $238,448.54 19
PY2022 Recipient $9,305.90 2
PY2022 Principal investigator $148,714.11 15
PY2021 Recipient $23,426.10 9
PY2021 Principal investigator $291,910.30 51
PY2020 Principal investigator $331,623.31 81
PY2019 Recipient $171,128.64 8
PY2019 Principal investigator $245,916.89 132

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

140 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $4,454.12 12/31/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670118615
Principal investigator 1 Allergan Inc. $220.00 12/31/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670119130
Principal investigator 1 Allergan Inc. $264.42 12/31/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670119433
Principal investigator 1 Allergan Inc. $615.00 12/31/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670119721
Principal investigator 1 Allergan Inc. $1,710.00 12/31/2019 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES GULFCOAST CLINIC
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder No dispute reported 06/30/2026 670121687
Principal investigator 1 Supernus Pharmaceuticals, Inc. $14.71 12/30/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705881047
Principal investigator 1 Supernus Pharmaceuticals, Inc. $14.71 12/30/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705881049
Principal investigator 1 Allergan Inc. $225.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670115229
Principal investigator 1 Supernus Pharmaceuticals, Inc. $6.10 12/16/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880959
Principal investigator 1 Supernus Pharmaceuticals, Inc. $6.10 12/16/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880961
Principal investigator 1 Allergan Inc. $6,836.60 12/12/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670108659
Principal investigator 1 Allergan Inc. $2,000.00 12/10/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670107319
Principal investigator 1 Allergan Inc. $500.00 12/03/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670105539
Principal investigator 1 Allergan Inc. $750.00 12/03/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670105543
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7.32 11/20/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880753
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7.32 11/20/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880755
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2.84 11/20/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880841
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2.84 11/20/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880843
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7.29 11/08/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880635
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7.29 11/08/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880637
Principal investigator 1 Alkermes, Inc. $50.00 11/01/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522523
Principal investigator 1 Supernus Pharmaceuticals, Inc. $41.50 10/28/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880355
Principal investigator 1 Supernus Pharmaceuticals, Inc. $41.50 10/28/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880357
Principal investigator 1 Supernus Pharmaceuticals, Inc. $48.00 10/28/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880441
Principal investigator 1 Supernus Pharmaceuticals, Inc. $48.00 10/28/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880443
Principal investigator 1 Allergan Inc. $225.00 10/22/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670088665
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,062.42 10/21/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880013
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,062.42 10/21/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880015
Principal investigator 1 Supernus Pharmaceuticals, Inc. $137.18 10/21/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880099
Principal investigator 1 Supernus Pharmaceuticals, Inc. $137.18 10/21/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880101
Principal investigator 1 Supernus Pharmaceuticals, Inc. $240.76 10/21/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880187
Principal investigator 1 Supernus Pharmaceuticals, Inc. $240.76 10/21/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880191
Principal investigator 1 Supernus Pharmaceuticals, Inc. $177.92 10/21/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705880277
Principal investigator 1 Supernus Pharmaceuticals, Inc. $33.90 10/19/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705879947
Principal investigator 1 Supernus Pharmaceuticals, Inc. $33.90 10/19/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705879949
Principal investigator 1 Supernus Pharmaceuticals, Inc. $114.81 10/19/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705879973
Principal investigator 1 Supernus Pharmaceuticals, Inc. $114.81 10/19/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705879987
Principal investigator 1 Allergan Inc. $775.20 10/15/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670084547
Principal investigator 1 Supernus Pharmaceuticals, Inc. $14.64 10/15/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705879877
Principal investigator 1 Supernus Pharmaceuticals, Inc. $14.64 10/15/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705879879
Principal investigator 1 Supernus Pharmaceuticals, Inc. $318.00 10/11/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705879853
Principal investigator 1 Supernus Pharmaceuticals, Inc. $318.00 10/11/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705879855
Principal investigator 1 Supernus Pharmaceuticals, Inc. $50.00 10/11/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705879857
Principal investigator 1 Supernus Pharmaceuticals, Inc. $50.00 10/11/2019 Non-covered Recipient Individual A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705879859
Principal investigator 1 Allergan Inc. $169.00 10/10/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EFFICACY AND SAFETY STUDY OF RAPASTINEL FOR RAPID TREATMENT OF SYMPTOMS OF DEPRESSION AND SUICIDALITY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670084135
Principal investigator 1 Allergan Inc. $169.00 10/08/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM-EXTENDED ACCESS PROTOCOL FOR RAPASTINEL AS ADJUNCTIVE OR MONOTHERAPY TREATMENT IN PATIENTS WITH MAYOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670083393
Principal investigator 1 Alkermes, Inc. $90.90 10/01/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522515
Principal investigator 1 Alkermes, Inc. $90.90 10/01/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522517
Principal investigator 1 Alkermes, Inc. $6.81 10/01/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522519
Principal investigator 1 Alkermes, Inc. $6.81 10/01/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522521
Principal investigator 1 Allergan Inc. $2,883.80 10/01/2019 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES GULFCOAST CLINIC
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder No dispute reported 06/30/2026 670081683
Principal investigator 1 Allergan Inc. $254.00 10/01/2019 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES GULFCOAST CLINIC
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder No dispute reported 06/30/2026 670081687
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $43,405.30 09/16/2019 Non-covered Recipient Entity
KPB B TRUST INC
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686157783
Principal investigator 1 Alkermes, Inc. $1,316.99 09/13/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522525
Principal investigator 1 Allergan Inc. $2,631.50 09/10/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670074019
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,358.80 09/03/2019 Non-covered Recipient Entity
KPB B TRUST INC
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686163945
Principal investigator 1 Alkermes, Inc. $50.00 09/01/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522513
Principal investigator 1 Alkermes, Inc. $39.39 08/21/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522505
Principal investigator 1 Alkermes, Inc. $39.39 08/21/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522507
Principal investigator 1 Alkermes, Inc. $2.90 08/21/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522509
Principal investigator 1 Alkermes, Inc. $2.90 08/21/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522511
Recipient Arbor Pharmaceuticals, Inc. $7,490.59 08/21/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658979
Principal investigator 1 Sunovion Pharmaceuticals Inc. $265.50 08/15/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914279
Principal investigator 1 Sunovion Pharmaceuticals Inc. $3.40 08/15/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154667
Principal investigator 1 Allergan Inc. $9,689.05 08/13/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670064325
Principal investigator 1 Sunovion Pharmaceuticals Inc. $276.25 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914725
Principal investigator 1 Sunovion Pharmaceuticals Inc. $276.25 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914727
Principal investigator 1 Sunovion Pharmaceuticals Inc. $276.25 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914729
Principal investigator 1 Sunovion Pharmaceuticals Inc. $552.50 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914731
Principal investigator 1 Sunovion Pharmaceuticals Inc. $552.50 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914733
Principal investigator 1 Sunovion Pharmaceuticals Inc. $620.00 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914735
Principal investigator 1 Sunovion Pharmaceuticals Inc. $835.00 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914737
Principal investigator 1 Sunovion Pharmaceuticals Inc. $1,500.00 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914739
Principal investigator 1 Sunovion Pharmaceuticals Inc. $4,520.10 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914747
Principal investigator 1 Sunovion Pharmaceuticals Inc. $11,283.31 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914755
Principal investigator 1 Sunovion Pharmaceuticals Inc. $3.54 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155539
Principal investigator 1 Sunovion Pharmaceuticals Inc. $3.54 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155543
Principal investigator 1 Sunovion Pharmaceuticals Inc. $3.54 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155547
Principal investigator 1 Sunovion Pharmaceuticals Inc. $7.08 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155551
Principal investigator 1 Sunovion Pharmaceuticals Inc. $7.08 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155555
Principal investigator 1 Sunovion Pharmaceuticals Inc. $7.94 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155559
Principal investigator 1 Sunovion Pharmaceuticals Inc. $10.70 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155563
Principal investigator 1 Sunovion Pharmaceuticals Inc. $19.22 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155567
Principal investigator 1 Sunovion Pharmaceuticals Inc. $57.93 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155579
Principal investigator 1 Sunovion Pharmaceuticals Inc. $144.62 08/08/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155593
Principal investigator 1 Alkermes, Inc. $80.00 08/01/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522501
Principal investigator 1 Alkermes, Inc. $25.00 08/01/2019 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 653522503
Principal investigator 1 Allergan Inc. $400.00 07/29/2019 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES GULFCOAST CLINIC
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder No dispute reported 06/30/2026 670061097
Principal investigator 1 Allergan Inc. $1,500.00 07/29/2019 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES GULFCOAST CLINIC
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder No dispute reported 06/30/2026 670061099
Principal investigator 1 Allergan Inc. $250.00 07/29/2019 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES GULFCOAST CLINIC
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder No dispute reported 06/30/2026 670061115
Recipient Arbor Pharmaceuticals, Inc. $5,000.00 07/10/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658965
Recipient Arbor Pharmaceuticals, Inc. $7,839.24 07/10/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658971
Principal investigator 1 Allergan Inc. $27,438.85 07/09/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670055647
Principal investigator 1 Sunovion Pharmaceuticals Inc. $286.25 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914281
Principal investigator 1 Sunovion Pharmaceuticals Inc. $286.25 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914283
Principal investigator 1 Sunovion Pharmaceuticals Inc. $286.25 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914285
Principal investigator 1 Sunovion Pharmaceuticals Inc. $328.75 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914287
Principal investigator 1 Sunovion Pharmaceuticals Inc. $351.25 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914289
Principal investigator 1 Sunovion Pharmaceuticals Inc. $351.25 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914291
Principal investigator 1 Sunovion Pharmaceuticals Inc. $432.50 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914293
Principal investigator 1 Sunovion Pharmaceuticals Inc. $432.50 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914295
Principal investigator 1 Sunovion Pharmaceuticals Inc. $680.00 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914297
Principal investigator 1 Sunovion Pharmaceuticals Inc. $702.50 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914299
Principal investigator 1 Sunovion Pharmaceuticals Inc. $1,000.00 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914301
Principal investigator 1 Sunovion Pharmaceuticals Inc. $3.66 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154669
Principal investigator 1 Sunovion Pharmaceuticals Inc. $3.66 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154673
Principal investigator 1 Sunovion Pharmaceuticals Inc. $3.66 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154677
Principal investigator 1 Sunovion Pharmaceuticals Inc. $4.21 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154679
Principal investigator 1 Sunovion Pharmaceuticals Inc. $4.50 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154683
Principal investigator 1 Sunovion Pharmaceuticals Inc. $4.50 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154687
Principal investigator 1 Sunovion Pharmaceuticals Inc. $5.54 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154691
Principal investigator 1 Sunovion Pharmaceuticals Inc. $5.54 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154695
Principal investigator 1 Sunovion Pharmaceuticals Inc. $8.71 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154699
Principal investigator 1 Sunovion Pharmaceuticals Inc. $9.00 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154703
Principal investigator 1 Sunovion Pharmaceuticals Inc. $12.81 07/05/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154707
Principal investigator 1 Allergan Inc. $8,095.90 06/11/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670050939
Principal investigator 1 Sunovion Pharmaceuticals Inc. $3,076.88 05/09/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914743
Principal investigator 1 Sunovion Pharmaceuticals Inc. $39.43 05/09/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155573
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,703.40 05/02/2019 Non-covered Recipient Entity
KPB B TRUST INC
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686163943
Recipient Arbor Pharmaceuticals, Inc. $36,173.15 05/01/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658957
Recipient Arbor Pharmaceuticals, Inc. $47,232.58 04/17/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658949
Principal investigator 1 Sunovion Pharmaceuticals Inc. $4,897.41 04/10/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914749
Principal investigator 1 Sunovion Pharmaceuticals Inc. $62.77 04/10/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155583
Principal investigator 1 Sunovion Pharmaceuticals Inc. $28,657.73 03/14/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 629914303
Principal investigator 1 Sunovion Pharmaceuticals Inc. $4,390.88 03/14/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914745
Principal investigator 1 Sunovion Pharmaceuticals Inc. $367.33 03/14/2019 Non-covered Recipient Entity
KPB&B TRUST INC
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder No dispute reported 06/30/2026 632154711
Principal investigator 1 Sunovion Pharmaceuticals Inc. $56.28 03/14/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155577
Principal investigator 2 Otsuka Pharmaceutical Development & Commercialization, Inc. $20,331.42 03/11/2019 Non-covered Recipient Entity
KPB&B TRUST INC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF BREXPIPRAZOLE 1 - 3 MGDAY AS MONOTHERAPY OR AS COMBINATION THERAPY IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 696053687
Principal investigator 1 Sunovion Pharmaceuticals Inc. $5,268.93 03/07/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914751
Principal investigator 1 Sunovion Pharmaceuticals Inc. $67.53 03/07/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155587
Recipient Arbor Pharmaceuticals, Inc. $2,500.00 03/06/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658941
Recipient Arbor Pharmaceuticals, Inc. $40,248.65 02/21/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658931
Recipient Arbor Pharmaceuticals, Inc. $24,644.43 02/11/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658921
Principal investigator 1 Sunovion Pharmaceuticals Inc. $2,674.68 02/07/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914741
Principal investigator 1 Sunovion Pharmaceuticals Inc. $34.28 02/07/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155569
Principal investigator 1 Sunovion Pharmaceuticals Inc. $6,392.23 01/29/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914753
Principal investigator 1 Sunovion Pharmaceuticals Inc. $81.93 01/29/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155591
Principal investigator 1 Sunovion Pharmaceuticals Inc. $12,450.07 01/10/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 629914757
Principal investigator 1 Sunovion Pharmaceuticals Inc. $159.58 01/10/2019 Non-covered Recipient Entity
KPB&B TRUST INC
Dasotraline Binge Eating Disorder Extension Study No dispute reported 06/30/2026 632155597
Principal investigator 1 Allergan Inc. $775.20 01/03/2019 Non-covered Recipient Entity
KPB&B TRUST INCORPORATED DBA GULFCOAST
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670014992